Tempest Therapeutics, Inc. (TPST) — 10-K Filings
All 10-K filings from Tempest Therapeutics, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Tempest Shifts Focus to CAR-T, Seeks Partners for Phase 3-Ready HCC Drug
— Mar 30, 2026 Risk: high
Tempest Therapeutics, Inc. (TPST) reported a strategic shift in its 2025 fiscal year, expanding its pipeline through the acquisition of dual-targeting CAR-T pro -
Tempest Therapeutics Files 2024 10-K
— Mar 27, 2025 Risk: medium
Tempest Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Millendo -
Tempest Therapeutics Files 2023 Annual Report on Form 10-K
— Mar 19, 2024 Risk: medium
Tempest Therapeutics, Inc. (TPST) filed a Annual Report (10-K) with the SEC on March 19, 2024. Tempest Therapeutics, Inc. filed its annual report for the fiscal
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX